HomeGeneticsConditionCongenital generalized lipodystrophy
Back to Condition
Congenital generalized lipodystrophy
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

Congenital generalized lipodystrophy

Congenital generalized lipodystrophy is a rare condition characterized by an almost total lack of fatty (adipose) tissue, leading to a muscular appearance and serious health problems from fat storage in other organs.

Overview

Congenital generalized lipodystrophy (also called Berardinelli-Seip congenital lipodystrophy) is a rare condition characterized by an almost total lack of fatty (adipose) tissue in the body and a very muscular appearance. Adipose tissue is found in many parts of the body, including beneath the skin and surrounding the internal organs. It stores fat for energy and also provides cushioning. Congenital generalized lipodystrophy is part of a group of related disorders known as lipodystrophies, which are all characterized by a loss of adipose tissue. A shortage of adipose tissue leads to the storage of fat elsewhere in the body, such as in the liver and muscles, which causes serious health problems.

The signs and symptoms of congenital generalized lipodystrophy are usually apparent from birth or early childhood. One of the most common features is insulin resistance, a condition in which the body's tissues are unable to recognize , a hormone that normally helps to regulate levels of blood glucose, also called blood sugar. Insulin resistance may develop into a more serious disease called diabetes mellitus. Most affected individuals also have high levels of fats called triglycerides circulating in the bloodstream (hypertriglyceridemia), which can lead to the development of small yellow deposits of fat under the skin called eruptive xanthomas and inflammation of the (pancreatitis). Additionally, congenital generalized lipodystrophy causes an abnormal buildup of fats in the (hepatic steatosis), which can result in an enlarged liver (hepatomegaly) and liver failure. Some affected individuals develop a form of heart disease called , which can lead to heart failure and an abnormal heart rhythm (arrhythmia) that can cause sudden death.

People with congenital generalized lipodystrophy have a distinctive physical appearance. They appear very muscular because they have an almost complete absence of adipose tissue and an overgrowth of muscle tissue. A lack of adipose tissue under the skin also makes the veins appear prominent. Affected individuals tend to have prominent bones above the eyes (), large hands and feet, and a prominent belly button (umbilicus). Affected females may have an enlarged clitoris (clitoromegaly), an increased amount of body hair (hirsutism), irregular menstrual periods, and multiple cysts on the , which may be related to hormonal changes. Many people with this disorder develop acanthosis nigricans, a skin condition related to high levels of insulin in the bloodstream. Acanthosis nigricans causes the skin in body folds and creases to become thick, dark, and velvety.

Researchers have described four types of congenital generalized lipodystrophy, which are distinguished by their genetic cause. The types also have some differences in their typical signs and symptoms. For example, in addition to the features described above, some people with congenital generalized lipodystrophy type 1 develop cysts in the long bones of the arms and legs after puberty. Type 2 can be associated with intellectual disability, which is usually mild to moderate. Type 3 appears to cause poor growth and short stature, along with other health problems. Type 4 is associated with muscle weakness, delayed development, joint abnormalities, a narrowing of the lower part of the stomach (pyloric stenosis), and severe arrhythmia that can lead to sudden death.

Frequency

Congenital generalized lipodystrophy has an estimated prevalence of 1 in 10 million people worldwide. Between 300 and 500 people with the condition have been described in the medical literature. Although this condition has been reported in populations around the world, it appears to be more common in certain regions of Lebanon and Brazil.

Causes

Mutations in the AGPAT2, BSCL2, CAV1, and CAVIN1 genes cause congenital generalized lipodystrophy types 1 through 4, respectively. The proteins produced from these genes play important roles in the development and function of adipocytes, which are the fat-storing cells in adipose tissue. Mutations in any of these genes reduce or eliminate the function of their respective proteins, which impairs the development, structure, or function of adipocytes and makes the body unable to store and use fats properly. These abnormalities of adipose tissue disrupt hormones and affect many of the body's organs, resulting in the varied signs and symptoms of congenital generalized lipodystrophy.

Some of the genes associated with congenital generalized lipodystrophy also play roles in other cells and tissues. For example, the protein produced from the BSCL2 gene is also present in the brain, although its function is unknown. A loss of this protein in the brain may help explain why congenital generalized lipodystrophy type 2 is sometimes associated with intellectual disability.

In some people with congenital generalized lipodystrophy, no mutations have been found in any of the genes listed above. Researchers are looking for additional genetic changes associated with this disorder.

Learn more about the genes associated with Congenital generalized lipodystrophy

  • AGPAT2
  • BSCL2
  • CAV1
  • CAVIN1

Inheritance

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Other Names for This Condition

  • Berardinelli-Seip congenital lipodystrophy
  • Berardinelli-Seip syndrome
  • Brunzell syndrome (with bone cysts)
  • BSCL
  • Generalized lipodystrophy
  • Lipodystrophy, congenital generalized
  • Seip syndrome
  • Total lipodystrophy

Frequently Asked Questions

Yes. Recombinant leptin (metreleptin) is approved for generalized lipodystrophy and can improve insulin resistance, lower triglycerides, and reduce hepatic fat. It is given by daily subcutaneous injection and requires monitoring for antibodies and liver function. Traditional diabetes drugs (metformin, GLP‑1 agonists) and fibrates for triglycerides are also used adjunctively. Discuss eligibility and insurance coverage with a metabolic specialist.
While CGL cannot restore missing adipose tissue, a low‑carbohydrate, high‑protein diet can reduce hepatic steatosis and triglyceride spikes. Limit simple sugars, fructose, and saturated fats; prioritize whole grains, legumes, lean meats, and omega‑3‑rich fish. Regular aerobic activity (30 minutes, most days) improves insulin sensitivity, but avoid excessive high‑intensity workouts that may increase muscle breakdown.
Newborns with congenital generalized lipodystrophy (CGL) typically have a strikingly lean, muscular appearance from birth, with absent subcutaneous fat on the limbs, trunk, and face. The skin may feel thin and the veins are often prominent. If you notice these features together with early‑onset metabolic abnormalities (e.g., high blood sugar or triglycerides), discuss genetic testing for known CGL genes (AGPAT2, BSCL2, CAV1, PTRF) with your pediatrician.
Even before diabetes develops, children with CGL often show elevated fasting insulin and impaired glucose tolerance. Obtain fasting glucose, fasting insulin, and calculate the HOMA‑IR index. A lipid panel (triglycerides, LDL, HDL) should also be checked because hypertriglyceridemia appears early. Repeat these tests every 6–12 months or sooner if symptoms change.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA